Analyst Reco. Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-04-24 pm EDT			5-day change	1st Jan Change
48.86 ^USD	-0.27%		+2.13%	-4.77%

Apr. 23	Germany's Evotec appoints Christian Wojczewski as CEO	RE
Apr. 23	Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	Apr. 22	MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	Apr. 18	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	Apr. 15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	Apr. 15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	Apr. 12	MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	Apr. 09	MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85	Mar. 11	MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating	Feb. 06	MT
Redburn Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $54 From $77	Feb. 06	MT
That's good enough for investors	Feb. 06
ANALYST RECOMMENDATIONS : Chevron, McDonald's, Palantir, Sainsbury, Tesla...	Feb. 06
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $41 From $42, Incorporates Mirati Transaction Into Model; Underweight Kept	Feb. 05	MT
UBS Cuts Bristol-Myers Squibb Price Target to $52 From $57, Maintains Neutral Rating	Jan. 17	MT
Berenberg: M&A Dealmaking in Pharmaceutical Sector to Further Accelerate in 2024	Jan. 09	MT
BofA Securities Downgrades Bristol-Myers Squibb to Neutral From Buy, Price Target is $60	Jan. 03	MT
Morgan Stanley Cuts Price Target on Bristol-Myers Squibb to $42 From $50, Keeps Underweight Rating	Dec. 12	MT
Are rate cuts are coming early next year?	Dec. 07
Joe Biden and Xi Jinping almost made up	Nov. 16
Cantor Fitzgerald Downgrades Bristol-Myers Squibb to Neutral From Overweight, Cuts Price Target to $55 From $68	Nov. 15	MT
Deutsche Bank Initiates Coverage on Bristol-Myers Squibb With Hold Rating, $55 Price Target	Nov. 09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST